ArticlePloS one2014
Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.PloS one · 2015Pooled it
- Analytical Methods for Fluid Biomarkers in Alzheimer's Disease from Discovery to Clinical Implementation.International journal of molecular sciences · 2026Review
- Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases.Scientific reports · 2025Article
- A General Linear Mixed Effect Model to Infer Biomarker Correlations by Bridging Retrospectively Measured Data Across Multiple Studies.Statistics in medicine · 2025Article
- Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.European archives of psychiatry and clinical neuroscience · 2025Article
- Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.Neurology · 2024Article
- Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer's disease in cerebrospinal fluid.Practical laboratory medicine · 2024Article
- Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.Journal of neurochemistry · 2024Article
- Unlocking the potential of circulating small extracellular vesicles in neurodegenerative disease through targeted biomarkers and advancements in biosensing.Exploration of biomat-x · 2024Article
- Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
- Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.Brain : a journal of neurology · 2022Article
- Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.International journal of molecular sciences · 2022Article
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.JAMA neurology · 2022Article
- Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.Alzheimer's research & therapy · 2022Article
- Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research.Journal of Alzheimer's disease : JAD · 2021Article
- ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.Brain : a journal of neurology · 2020Article
- The Use of Antibody Arrays in the Discovery of New Plasma Biomarkers for Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrospinal fluid (CSF) biomarkers are increasingly being used for diagnosis of Alzheimer's disease (AD).
objectiveWe investigated the influence of CSF intralaboratory and interlaboratory variability on diagnostic CSF-based AD classification of subjects and identified causes of this variation.
methodsWe measured CSF amyloid-β (Aβ) 1-42, total tau (t-tau), and phosphorylated tau (p-tau) by INNOTEST enzyme-linked-immunosorbent assays (ELISA) in a memory clinic population (n = 126). Samples were measured twice in a single or two laboratories that served as reference labs for CSF analyses in the Netherlands. Predefined cut-offs were used to classify CSF biomarkers as normal or abnormal/AD pattern.
resultsCSF intralaboratory variability was higher for Aβ1-42 than for t-tau and p-tau. Reanalysis led to a change in biomarker classification (normal vs. abnormal) of 26% of the subjects based on Aβ1-42, 10% based on t-tau, and 29% based on p-tau. The changes in absolute biomarker concentrations were paralleled by a similar change in levels of internal control samples between different assay lots. CSF interlaboratory variability was higher for p-tau than for Aβ1-42 and t-tau, and reanalysis led to a change in biomarker classification of 12% of the subjects based on Aβ1-42, 1% based on t-tau, and 22% based on p-tau.
conclusionsIntralaboratory and interlaboratory CSF variability frequently led to change in diagnostic CSF-based AD classification for Aβ1-42 and p-tau. Lot-to-lot variation was a major cause of intralaboratory variability. This will have implications for the use of these biomarkers in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.